Observational Study
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Psychiatry. Sep 19, 2024; 14(9): 1354-1363
Published online Sep 19, 2024. doi: 10.5498/wjp.v14.i9.1354
Shugan Jieyu capsule effects on peripheral blood micro-124, micro-132, and brain-derived neurotrophic factor in patients with mild to moderate depression
Xian Zhang, Yang Liu, Hua-Fei Tang, Feng Jiang, Chun-Liang Chen, Ting-Ting Wang, Hui-Zhong Gu, Qiang Zhao, Rui Ma
Xian Zhang, Yang Liu, Hua-Fei Tang, Feng Jiang, Chun-Liang Chen, Ting-Ting Wang, Hui-Zhong Gu, Qiang Zhao, Rui Ma, Department of Pharmacy, The 305 Hospital of People’s Liberation Army, Beijing 100017, China
Co-first authors: Xian Zhang and Yang Liu.
Co-corresponding authors: Qiang Zhao and Rui Ma.
Author contributions: Zhang X and Liu Y contributed equally to this work. Zhang X and Liu Y designed the study and performed the experiments; Tang HF, Jiang F, Chen CL, Wang TT, and Gu HZ collected the data; Zhao Q analyzed the data; Ma R prepared the manuscript, they are the co-corresponding authors of this manuscript. All the authors have read and approved the final version of the manuscript.
Supported by the 305 Hospital Independent Scientific Research Fund, 2024, No. 24ZZJJLW-022.
Institutional review board statement: This study was approved by the Ethics Committee of Hospital of Beijing Armed Police Forces the initiator of the multi-center joint study.
Informed consent statement: Informed consent was obtained from all subjects involved in the study. Written informed consent has been obtained from the patients to publish this paper.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: The data presented in this study are available on request from the corresponding author.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Rui Ma, MD, Doctor, Department of Pharmacy, The 305 Hospital of People’s Liberation Army, No. A13 Wenjin Street, Xicheng District, Beijing 100017, China. maruipla@126.com
Received: June 12, 2024
Revised: July 4, 2024
Accepted: August 5, 2024
Published online: September 19, 2024
Processing time: 91 Days and 2.5 Hours
Core Tip

Core Tip: The study examines the effects of Shugan Jieyu capsules on patients with mild to moderate depression following percutaneous coronary intervention for coronary heart disease. The results indicate significant improvements in depressive symptoms, biochemical markers such as miR-124, miR-132, and brain-derived neurotrophic factor, as well as immune function. Shugan Jieyu capsules outperformed escitalopram oxalate tablets in reducing depression severity and adverse reactions, suggesting their potential as a safer and more effective treatment alternative for post-percutaneous coronary intervention depression.